… observed in numerous primary central nervous system tumors as … -BRAF treated with an
analog of vemurafenib exhibit … cases of dramatic and sometimes-sustained response to BRAFi …

… , we think that the remission observed is due to the BRAF inhibition. Optimal duration of …
Dramatic response of a BRAF V600E‐mutated primary CNS histiocytic sarcoma to vemurafenib. …

… the diagnoses of histiocytic sarcoma (HS), Langerhans cell sarcoma 192 and interdigitating
dendritic cell sarcoma, … We also thank Roche for providing vemurafenib and/or cobimetinib. …

… published cases of primary central nervous system histiocytic sarcoma (PCNSHS) … It has
been demonstrated that vemurafenib treatment resulted in a 3-month response in a BRAF p.…

… [27] treated a patient with isolated central nervous system histiocytic sarcoma harboring a
BRAF p.V600E mutation with vemurafenib who had a dramatic clinical and radiologic …

… Histiocytic sarcoma (HS) is a malignant hematopoietic … On imaging, HS mimics a malignant
primary CNS tumor, with … V600E mutations may respond to inhibitors (eg, vemurafenib)…

… response to the BRAF-V600E inhibitor vemurafenib was reported in a refractory case of
BRAF-V600E-mutated primary CNS-… for histiocytic sarcoma of the central nervous system. Leuk …

… Histiocytic sarcoma (HS) is a highly malignant hematopoietic neoplasm that rarely arises in
the central nervous system (CNS)… Histiocytic sarcoma (HS) is a rare malignant hematopoietic …

… to the CNS-JXG diagnosis; CNS histiocytic sarcoma with … series to date of BRAF V600E
mutated pediatric JXG family … V600E mutation, including both primary CNS (ie, pleomorphic …

… responses to a BRAF-V600E inhibitor, vemurafenib, have been shown in a refractory
BRAF-V600E-mutated primary CNS … of disseminated or CNS histiocytic sarcoma remains very …